Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Kelly CM, Pritchard KI.

J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6. No abstract available.

PMID:
22395645
[PubMed - indexed for MEDLINE]
Free Article
2.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA.

J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31. No abstract available.

PMID:
22851270
[PubMed - indexed for MEDLINE]
Free Article
3.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Stanton V Jr.

J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31. No abstract available.

PMID:
22851267
[PubMed - indexed for MEDLINE]
Free Article
4.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Pharoah PD, Abraham J, Caldas C.

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31. No abstract available.

PMID:
22851268
[PubMed - indexed for MEDLINE]
Free Article
5.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

PMID:
22395643
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

PMID:
22395644
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Gurwitz D, Newman W.

J Natl Cancer Inst. 2008 Sep 17;100(18):1331; author reply 1332-4. doi: 10.1093/jnci/djn269. Epub 2008 Sep 9. No abstract available.

PMID:
18780871
[PubMed - indexed for MEDLINE]
Free Article
8.

Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Chlebowski RT, Col N.

J Natl Cancer Inst. 2008 Sep 17;100(18):1331-2; author reply 132-3. doi: 10.1093/jnci/djn272. Epub 2008 Sep 9. No abstract available.

PMID:
18780870
[PubMed - indexed for MEDLINE]
Free Article
9.

Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.

Woods B, Veenstra D, Hawkins N.

Value Health. 2011 Dec;14(8):989-1001. doi: 10.1016/j.jval.2011.05.048. Epub 2011 Nov 12.

PMID:
22152167
[PubMed - indexed for MEDLINE]
10.

Overcoming recurrence risk: extended adjuvant endocrine therapy.

Cianfrocca M.

Clin Breast Cancer. 2008 Dec;8(6):493-500. doi: 10.3816/CBC.2008.n.059. Review.

PMID:
19073503
[PubMed - indexed for MEDLINE]
11.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
[PubMed - indexed for MEDLINE]
12.

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

Rae JM, Regan M, Leyland-Jones B, Hayes DF, Dowsett M.

J Clin Oncol. 2013 Jul 20;31(21):2753-5. doi: 10.1200/JCO.2013.49.4278. Epub 2013 Jun 17. No abstract available.

PMID:
23775974
[PubMed - indexed for MEDLINE]
Free Article
13.

Anastrozole.

Cuzick J.

Drugs Today (Barc). 2005 Apr;41(4):227-39. Review.

PMID:
16034487
[PubMed - indexed for MEDLINE]
14.

Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.

Dizdar O, Harputluoglu H, Altundag K.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1651; author reply 1651. No abstract available.

PMID:
18035222
[PubMed - indexed for MEDLINE]
15.

'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.

Buzdar AU; ATAC trialists' group.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):399-403.

PMID:
14623537
[PubMed - indexed for MEDLINE]
16.

The ethics of CYP2D6 testing for patients considering tamoxifen.

Hartman AR, Helft P.

Breast Cancer Res. 2007;9(2):103.

PMID:
17433116
[PubMed - indexed for MEDLINE]
Free PMC Article
17.
18.

CYP2D6 genotype and tamoxifen response.

Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA.

Breast Cancer Res. 2005 Jul 29;7(5):E6. No abstract available.

PMID:
16168100
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

DeGrendele H.

Clin Breast Cancer. 2003 Dec;4(5):311-2. No abstract available.

PMID:
14715105
[PubMed - indexed for MEDLINE]
20.

Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.

[No authors listed]

Health News. 2005 Dec;11(12):13-4. No abstract available.

PMID:
16416553
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk